197 related articles for article (PubMed ID: 35577640)
41. Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
Westra TA; Stirbu-Wagner I; Dorsman S; Tutuhatunewa ED; de Vrij EL; Nijman HW; Daemen T; Wilschut JC; Postma MJ
BMC Infect Dis; 2013 Feb; 13():75. PubMed ID: 23390964
[TBL] [Abstract][Full Text] [Related]
42. Pros, cons, and ethics of HPV vaccine in teens-Why such controversy?
White MD
Transl Androl Urol; 2014 Dec; 3(4):429-34. PubMed ID: 26816799
[TBL] [Abstract][Full Text] [Related]
43. The HPV infection in males: an update.
Giraldi G; De Luca d'Alessandro E
Ann Ig; 2012; 24(6):497-506. PubMed ID: 23234187
[TBL] [Abstract][Full Text] [Related]
44. Committee Opinion No. 704: Human Papillomavirus Vaccination.
Obstet Gynecol; 2017 Jun; 129(6):1. PubMed ID: 28346275
[TBL] [Abstract][Full Text] [Related]
45. Committee Opinion No. 704 Summary: Human Papillomavirus Vaccination.
Obstet Gynecol; 2017 Jun; 129(6):1. PubMed ID: 28538494
[TBL] [Abstract][Full Text] [Related]
46. Impact of prophylactic human papillomavirus vaccines on dermatology and venereology.
Gross G
G Ital Dermatol Venereol; 2008 Aug; 143(4):259-65. PubMed ID: 18833082
[TBL] [Abstract][Full Text] [Related]
47. [The specifities of the HPV-genital infections in males].
Skerlev M; Ljubojevic S
Med Glas (Zenica); 2010 Aug; 7(2):89-95. PubMed ID: 21258302
[TBL] [Abstract][Full Text] [Related]
48. Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour.
Wolff E; Elfström KM; Haugen Cange H; Larsson S; Englund H; Sparén P; Roth A
Vaccine; 2018 Aug; 36(34):5160-5165. PubMed ID: 30017146
[TBL] [Abstract][Full Text] [Related]
49. Beyond cervical cancer: burden of other HPV-related cancers among men and women.
Chaturvedi AK
J Adolesc Health; 2010 Apr; 46(4 Suppl):S20-6. PubMed ID: 20307840
[TBL] [Abstract][Full Text] [Related]
50. Efficacy, effectiveness and safety of vaccination against human papillomavirus in males: a systematic review.
Harder T; Wichmann O; Klug SJ; van der Sande MAB; Wiese-Posselt M
BMC Med; 2018 Jul; 16(1):110. PubMed ID: 30016957
[TBL] [Abstract][Full Text] [Related]
51. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
[TBL] [Abstract][Full Text] [Related]
52. HPV vaccine update: new indications and controversies.
Mendoza N; Hernandez PO; Tyring SK
Skin Therapy Lett; 2011 Sep; 16(8):1-3. PubMed ID: 22089414
[TBL] [Abstract][Full Text] [Related]
53. Prophylactic HPV vaccination: past, present, and future.
Castle PE; Maza M
Epidemiol Infect; 2016 Feb; 144(3):449-68. PubMed ID: 26429676
[TBL] [Abstract][Full Text] [Related]
54. HPV vaccination and the effects on rates of HPV-related cancers.
St Laurent J; Luckett R; Feldman S
Curr Probl Cancer; 2018 Sep; 42(5):493-506. PubMed ID: 30041818
[TBL] [Abstract][Full Text] [Related]
55. Could the human papillomavirus vaccine prevent recurrence of ano-genital warts?: a systematic review and meta-analysis.
Husein-ElAhmed H
Int J STD AIDS; 2020 Jun; 31(7):606-612. PubMed ID: 32438856
[TBL] [Abstract][Full Text] [Related]
56. Current status of human papillomavirus vaccination.
Brotherton JM; Ogilvie GS
Curr Opin Oncol; 2015 Sep; 27(5):399-404. PubMed ID: 26258273
[TBL] [Abstract][Full Text] [Related]
57. Prevention of Human Papillomavirus Infection. Beyond Cervical Cancer: A Brief Review.
Medeiros R; Vaz S; Rebelo T; Figueiredo-Dias M
Acta Med Port; 2020 Mar; 33(3):198-201. PubMed ID: 32130098
[TBL] [Abstract][Full Text] [Related]
58. Cost-effectiveness of different human papillomavirus vaccines in Singapore.
Lee VJ; Tay SK; Teoh YL; Tok MY
BMC Public Health; 2011 Mar; 11():203. PubMed ID: 21453537
[TBL] [Abstract][Full Text] [Related]
59. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis.
Kim JJ
Lancet Infect Dis; 2010 Dec; 10(12):845-52. PubMed ID: 21051295
[TBL] [Abstract][Full Text] [Related]
60. Impact of the quadrivalent HPV vaccine on disease recurrence in men exposed to HPV Infection: a randomized study.
Coskuner ER; Ozkan TA; Karakose A; Dillioglugil O; Cevik I
J Sex Med; 2014 Nov; 11(11):2785-91. PubMed ID: 25124237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
